Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls
Table 6
Frequency of CNR1 polymorphisms in study and control groups.
A3813G (rs12720071)
(chi2)
A4895G (rs806368)
(chi2)
A/A
A/G
G/G
T/T
C/T
C/C
PCOS + NAFLD
64.41% (38)
68.42% (13)
50% (13)
0.35 (2.04)
58.82% (40)
57.69% (15)
87.5% (7)
0.27 (2.6)
PCOS − NAFLD
35.59% (21)
31.58% (6)
50% (13)
41.18% (28)
42.31% (11)
12.5% (1)
Control + NAFLD
48.48% (32)
28.57% (4)
66.67% (4)
0.24 (2.89)
46.3% (25)
46.88% (15)
100% (1)
0.57 (1.14)
Control − NAFLD
51.52% (34)
71.43% (10)
33.33% (2)
53.7% (29)
53.13% (17)
0.00% (0)
G1422A (rs1049353)
(chi2)
rs806381
(chi2)
A/A
G/A
G/G
A/A
G/A
G/G
PCOS + NAFLD
48% (12)
69.7% (23)
64.58% (31)
0.21 (3.05)
72% (18)
37.5% (9)
66.67% (28)
0.025 (7.36)
PCOS − NAFLD
52% (13)
30.3% (10)
35.42% (17)
28% (7)
62.5% (15)
33.33% (14)
Control + NAFLD
33.33% (4)
50% (14)
48.98% (24)
0.58 (1.07)
45% (18)
50% (21)
44.44% (8)
0.88 (0.26)
Control − NAFLD
66.67% (8)
50% (14)
51.02% (25)
55% (22)
50% (21)
55.56% (10)
rs10485170
(chi2)
rs6454674
(chi2)
A/A
A/G
G/G
T/T
G/T
G/G
PCOS + NAFLD
61.9% (52)
45.45% (5)
75% (6)
0.03 (7.04)
69.39% (34)
48.89% (22)
76.92% (10)
0.06 (5.62)
PCOS − NAFLD
38.1% (32)
54.55% (6)
25% (2)
30.61% (15)
51.11% (23)
23.08% (3)
Control + NAFLD
50% (41)
42.86% (9)
0%
0.56 (0.34)
48.98% (24)
50% (20)
42.86% (6)
0.89 (0.22)
Control − NAFLD
50% (41)
57.14% (12)
0%
51.02% (25)
50% (20)
57.14% (8)
PCOS + NAFLD: women with polycystic ovary syndrome and nonalcoholic fatty liver disease. PCOS − NAFLD: women with polycystic ovary syndrome without nonalcoholic fatty liver disease. Control + NAFLD: women from control group having nonalcoholic fatty liver disease. Control − NAFLD: women from control group without nonalcoholic fatty liver disease.
